Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
前景一片光明——有希望的试验结果表明癌症治疗与诊断正在提升到新的水平。
On Friday, Pfizer Inc (NYSE:PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ:MRNA) and Merck & Co (NYSE:MRK) also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine and Merck's blockbuster immunotherapy, Keytruda.
周五，辉瑞公司（NYSE:PFE）透露其治疗一种先进形式的肺癌的药物在晚期试验中显示出长期有希望的结果。周一，Moderna（纳斯达克:MRNA）和默沙东公司（纽交所:MRK）也报告了他们的联合黑色素瘤治疗的持久有效率，该治疗包括一种实验性的mRNA疫苗和默沙东的畅销的免疫治疗药Keytruda。
Pfizer Is Aiming To Set The Treatment Standard For Lung Cancer
辉瑞旨在为肺癌设定治疗标准
With encouraging results, Pfizer is getting another step closer to establish its drug as the new standard treatment for lung cancer. Lorbrena has helped patients live longer without their cancer...
随着令人鼓舞的结果，辉瑞离将其药物确立为新的肺癌标准治疗又进...
登录免费看全文
登录/注册